Nrx pharmaceuticals (nasdaq:nrxp) launches hope therapeutics, inc. at the bio ceo & investor conference 2024

Presentation available on nrx pharmaceuticals website at https://www.nrxpharma.com/hope-therapeutics/ key updates are as follows: nrx management is proposing to award 50% of founding shares in hope therapeutics to current shareholders together with a royalty coupon with an expected ex-dividend date in the near future, all subject to board approval dividend to be available to all shareholders who sign a covenant not to engage in short sales of nrx stock, subject to board approval hope anticipates having manufactured ketamine supplies for shipment under 503a pharmacy regulations by july 1, 2024 radnor, pa. , feb. 26, 2024 /prnewswire/ -- nrx pharmaceuticals, inc. (nasdaq: nrxp) ("nrx pharmaceuticals," the "company"), a clinical-stage biopharmaceutical company, today announced that dr. jonathan javitt, chairman and chief scientist of nrx pharmaceuticals, will present a corporate overview at the bio ceo & investor conference, which is scheduled to take place february 26-27, 2024, at the marriott marquis in new york city.
NRXP Ratings Summary
NRXP Quant Ranking